Nursing care
Acamprosate: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated September 2026
Short answer
Acamprosate reduces alcohol cravings after a patient has already stopped drinking; it has no effect on acute withdrawal and should not be started for someone still detoxifying. It is renally cleared, so the dose is adjusted for reduced kidney function and the drug is avoided in severe renal impairment.
Why this drug and not another
Acamprosate is chosen for maintaining abstinence, not for managing the acute phase of stopping drinking. It is thought to restore balance between excitatory and inhibitory neurotransmission disrupted by chronic alcohol use, which reduces protracted craving during recovery rather than producing sedation, aversion, or a deterrent reaction.
This makes it a fit for a patient who has already completed detoxification and is abstinent, or nearly so, at the start of therapy. It is not a substitute for benzodiazepine-based withdrawal management, and it will not prevent or treat seizures, autonomic instability, or delirium tremens if a patient is still in active withdrawal.
Administration and timing
Acamprosate is typically dosed three times daily, which is a higher pill burden than most comparable medications and a common source of missed doses; discuss the schedule with patients before starting rather than after adherence has already slipped. It can be taken with or without food.
Therapy is usually started once the patient is abstinent, ideally within days of stopping alcohol, and it is intended to continue for an extended course, often many months, alongside counselling or a support programme. It does not need to be tapered off in the way some CNS-acting medications do.
Monitoring parameters
Renal function is the central monitoring parameter, since acamprosate is eliminated by the kidneys and not metabolised by the liver. Check creatinine clearance before starting and periodically during treatment, and expect the prescriber to reduce the dose for moderate impairment and avoid the drug altogether in severe renal impairment.
Beyond renal labs, monitor for mood changes, since depression and, rarely, suicidal ideation have been reported during treatment for alcohol use disorder generally, and it can be difficult to separate a drug effect from the underlying course of recovery. Ask directly about mood and any thoughts of self-harm at follow-up visits.
Adverse effects to report
Diarrhoea is the most common adverse effect and can be significant enough to affect adherence; it usually appears early in treatment and often eases with continued use. Other gastrointestinal effects include nausea and flatulence, alongside less common complaints of dizziness or insomnia.
Report new or worsening depressed mood, anxiety, or any suicidal thinking without delay, since this needs prompt clinical reassessment rather than routine follow-up. Also report signs of significantly reduced kidney function, such as marked decrease in urine output or unexplained oedema, since these change whether the drug can be continued safely.
Contraindications and cautions
Severe renal impairment is the main contraindication, since acamprosate accumulates without adequate renal clearance. Pregnancy and breastfeeding warrant caution given limited safety data, and the drug should be used carefully in patients with a current or past history of depression given the reported association with mood symptoms.
Because acamprosate does nothing for acute withdrawal, do not use it as a stand-alone strategy for a patient still experiencing withdrawal symptoms; that patient needs an appropriate withdrawal protocol first. Confirm renal function is known and acceptable before the first dose is given, not assumed from history alone.
Teaching points the exam tests
The exam-style distinction is timing and mechanism: acamprosate treats the craving that follows abstinence, it does not treat withdrawal, and it is not a substitute for medically managed detoxification. A question that describes a patient still in acute withdrawal and asks whether acamprosate is appropriate is testing whether the nurse recognises that mismatch.
Teach patients that the three-times-daily schedule matters for steady effect and that missed doses reduce benefit rather than causing an acute reaction, unlike disulfiram. Reinforce that kidney function will be checked periodically, that the dose may be adjusted or the drug avoided if renal function is significantly reduced, and that diarrhoea early in treatment is common and usually improves without needing to stop the medication.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our mental health practice questions are the closest set to what this page covers.
Common questions
Does acamprosate treat alcohol withdrawal symptoms?
No, acamprosate does not treat acute alcohol withdrawal and will not prevent withdrawal seizures or delirium tremens. It is started after a patient has stopped drinking and is used to reduce ongoing cravings during the maintenance phase of recovery.
Why does acamprosate require a dose adjustment for kidney problems?
Acamprosate is eliminated almost entirely by the kidneys rather than metabolised by the liver, so reduced renal clearance causes it to accumulate. The dose is reduced for moderate renal impairment and the drug is generally avoided in severe impairment.
What is the most common side effect of acamprosate?
Diarrhoea is the most frequently reported side effect and tends to occur early in treatment, often improving as therapy continues. Nausea, flatulence, and occasional dizziness or insomnia are also reported.
How is acamprosate different from disulfiram?
Acamprosate reduces craving through effects on neurotransmitter balance and produces no reaction if the patient drinks, while disulfiram works by causing an unpleasant physical reaction to any alcohol intake. They can be used for different patient goals and are not interchangeable in mechanism or teaching points.
More on mental health